Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
WVE 
Wave Life Sciences Ltd (WVE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: WVE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $19.8
1 Year Target Price $19.8
| 9 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -52.77% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.25B USD | Price to earnings Ratio - | 1Y Target Price 19.8 |
Price to earnings Ratio - | 1Y Target Price 19.8 | ||
Volume (30-day avg) 13 | Beta -1.37 | 52 Weeks Range 5.28 - 16.73 | Updated Date 10/17/2025 |
52 Weeks Range 5.28 - 16.73 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -138.24% | Operating Margin (TTM) -606.5% |
Management Effectiveness
Return on Assets (TTM) -38.9% | Return on Equity (TTM) -171.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 931003968 | Price to Sales(TTM) 13.34 |
Enterprise Value 931003968 | Price to Sales(TTM) 13.34 | ||
Enterprise Value to Revenue 9.91 | Enterprise Value to EBITDA -10.12 | Shares Outstanding 159227061 | Shares Floating 65600880 |
Shares Outstanding 159227061 | Shares Floating 65600880 | ||
Percent Insiders 15.79 | Percent Institutions 87.16 |
Upturn AI SWOT
Wave Life Sciences Ltd
Company Overview
History and Background
Wave Life Sciences Ltd was founded in 2012. It focuses on developing stereopure nucleic acid therapies for genetically defined diseases.
Core Business Areas
- RNA Editing: Developing therapies using RNA editing technology.
- Antisense Therapies: Developing antisense oligonucleotide (ASO) therapies for a range of genetic diseases.
- Stereopure Oligonucleotides: Focusing on the development of stereopure oligonucleotides to enhance therapeutic properties.
Leadership and Structure
Paul Bolno is the President and CEO. The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- WVE-N531: An exon-skipping therapy for Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. Currently in clinical trials. Competitors include Sarepta Therapeutics (SRPT).
- WVE-003: A therapy for Huntington's disease (HD) targeting the HTT gene. Currently in clinical trials. Competitors include Roche (RHHBY) and Ionis Pharmaceuticals (IONS).
Market Dynamics
Industry Overview
The industry focuses on developing therapies for genetically defined diseases, including rare and orphan diseases. Key trends include advancements in gene therapy, RNA editing, and oligonucleotide therapies.
Positioning
Wave Life Sciences is positioned as a company specializing in stereopure nucleic acid therapies. Its competitive advantage lies in its focus on stereochemistry to enhance therapeutic properties.
Total Addressable Market (TAM)
The total addressable market for genetic therapies is estimated to be in the tens of billions of dollars. Wave is positioned with multiple clinical-stage programs targeting significant unmet needs.
Upturn SWOT Analysis
Strengths
- Proprietary stereopure oligonucleotide platform
- Focus on genetically defined diseases
- Experienced management team
- Clinical-stage programs
Weaknesses
- High R&D costs
- Reliance on clinical trial success
- Limited revenue generation
- Competition from larger pharmaceutical companies
Opportunities
- Potential FDA approvals for key pipeline programs
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in oligonucleotide technologies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from alternative therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- IONS
- SRPT
- RHHBY
- CRIS
Competitive Landscape
Wave Life Sciences faces competition from larger, more established companies with greater resources. Its advantage lies in its unique stereopure oligonucleotide platform, which may offer improved therapeutic properties.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancing pipeline programs and securing partnerships.
Future Projections: Future growth is dependent on successful clinical trial results and regulatory approvals.
Recent Initiatives: Focusing on advancing lead programs, exploring new therapeutic areas, and seeking strategic partnerships.
Summary
Wave Life Sciences is a clinical-stage biotechnology company focused on developing stereopure nucleic acid therapies. The company's strengths include its proprietary platform and focus on genetically defined diseases. However, it faces challenges related to high R&D costs, regulatory hurdles, and competition from larger companies. Successful clinical trials and strategic partnerships are crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data and market share estimates are subject to change and may not be entirely accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Wave Life Sciences Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-11-11 | President, CEO & Director Dr. Paul B. Bolno M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 287 | Website https://wavelifesciences.com |
Full time employees 287 | Website https://wavelifesciences.com | ||
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.